Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No
Executive Summary
The oncology player missed out on the first round of immune checkpoint inhibition and now some investors are wondering if the pharma needs to buy a rival to catch up. During the company’s second quarter sales call CEO Jimenez insisted Novartis has the internal expertise to execute.